NRG Therapeutics

Executive Summary

NRG Therapeutics is a clinical-stage neuroscience company based in Oxford, UK, pioneering disease-modifying treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS/MND) and Parkinson's disease. The company's unique approach targets mitochondrial dysfunction, a key driver of neuronal death, using first-in-class, orally available small molecules. Lead asset NRG-101 is currently in Phase 1 clinical trials for ALS, with preclinical work underway for Parkinson's. Leveraging deep insights into mitochondrial biology, NRG aims to slow or halt disease progression, addressing significant unmet needs in these devastating conditions. With a strong scientific foundation and a clear focus on CNS disorders, the company represents a promising player in the neuroscience drug development landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Clinical Data Readout for ALS Program50% success
• Q1 2027IND Submission for Parkinson's Disease Program40% success